Physician profile
Anna Wortel
NPI 1124393087
$1,714.91
in general payments reported to CMS, 2019-2025
7 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $116 · 2023: $230 · 2024: $763 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $518.67 | 2022-2024 | Livdelzi, Epclusa |
| Astrazeneca Pharmaceuticals Lp | $351.30 | 2024-2025 | Airsupra, Farxiga |
| Intercept Pharmaceuticals, INC. | $228.22 | 2021-2023 | Ocaliva |
| Novo Nordisk INC | $224.79 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $149.27 | 2025 | Terlivaz |
| Teva Pharmaceuticals USA, INC. | $131.09 | 2024 | Austedo Xr |
| Astellas Pharma US INC | $111.57 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wortel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.